Clinical Trial Update: FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating FOLFIRINOX with digoxin in patients with resectable pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• DIGOXIN (Digoxin)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: University of Nebraska | Conditions: Pancreas Cancer, Adenocarcinoma of the Pancreas | Phase 2 | Status: TERMINATED